[Ref No. T10759]
University of Tasmania researchers have developed a novel therapeutic composition based on Metallothionein (MT). MT is a naturally occurring protein well documented as being involved in endogenous multi-modal reparative processes associated with neurodegenerative and other indications. MT has an excellent toxicology profile. The University of Tasmania has protected therapeutic applications of MT.
Under a separate patent, the University of Tasmania has protected peptide analogues of MT. The patent protection applies across any therapeutic applications of MT, (the subject of this patent) providing a strong intellectual property position for the development of any derivatives or synthetic analogues of MT. The value proposition is access to a defensive patent position around a wide range therapeutic applications of Metallothionein.
This technology is available for licensing opportunities to interested industry partners.
Proof of Concept
Prof Adrian West, A/Prof Meng Chuah, Prof James Vickers, and Prof Roger Chung
Australian Patent Application No. 2003233259 (Granted), United States Patent No. 8,691,765 (Granted), European Patent Application No. 03727024.6 (Pending)
"New insight into the molecular pathways of metallothionein-mediated neuroprotection and regeneration". R. S. Chung, J. Hidalgo and A. K. West; Journal of Neurochemistry. Volume 104, Issue 1, pages 14–20, January 2008
Metallothionein, neuronal growth, Alzheimer's, Parkinson's, Motor Neuron Disease, head injury